ACADIA Pharmaceuticals Inc. (ACAD) — Analyst outlook / Analyst consensus target is. Based on 37 analyst ratings, the consensus is bullish — 26 Buy, 10 Hold, 1 Sell.
The consensus price target is $34.78 (low: $29.00, high: $40.00), representing an upside of 57.9% from the current price $22.02.
Analysts estimate Earnings Per Share (EPS) of $0.72 and revenue of $0.97B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.37 vs est $0.72 (beat +90%). 2025: actual $2.32 vs est $0.81 (beat +186.7%). Analyst accuracy: 44%.
ACAD Stock — 12-Month Price Forecast
$34.78
▲ +57.95% Upside
Average Price Target
Based on 37 Wall Street analysts offering 12-month price targets for ACADIA Pharmaceuticals Inc., the average price target is $34.78, with a high forecast of $40.00, and a low forecast of $29.00.
The average price target represents a +57.95% change from the last price of $22.02.
Highest Price Target
$40.00
Average Price Target
$34.78
Lowest Price Target
$29.00
ACAD Analyst Ratings
Buy
Based on 37 analysts giving stock ratings to ACADIA Pharmaceuticals Inc. in the past 3 months
EPS Estimates — ACAD
44%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $1.37
vs Est $0.72
▲ 47.4% off
2025
Actual $2.32
vs Est $0.81
▲ 65.1% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — ACAD
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.958B
vs Est $0.969B
▼ 1.1% off
2025
Actual $1.072B
vs Est $1.081B
▼ 0.9% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
